This incretin effect helps to lower blood glucose levels after meals
Sackmann-Sala, L., Ding, J., Frohman, L
Scholz C, Johansen MJ, Newman R, Andreeff M , Konopleva M, Madden T
Providers manage GLP-1 titration based on response, side effects, and progress
Bimagrumab addresses a critical unmet need. Mark Pruzanski The advantage: While people on GLP-1 agonists tend to gain back any weight lost if they stop taking the meds, that might not be the case for bimagrumab 12 weeks after their last dose, the people in the 1,000-person phase 2 trial had yet to regain any weight
Argument in favor: Others say that if Medicare covers the cost of these drugs, it could help more people afford these medications and improve health and quality of life for people who are overweight